Moteur de recherche d’entreprises européennes

Financement de l’UE (5 331 000 €) : Réduction des risques liés à la neurotoxicité dans la découverte de médicaments précliniques Hor 01/03/2019 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Réduction des risques liés à la neurotoxicité dans la découverte de médicaments précliniques

The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.


A. Persidis & SIA ΟΕ 406 800 €
Alcediag 583 300 €
Astrazeneca AB 0,00 €
Farmaceutski Fakultet Univerziteta U Beogradu 696 150 €
Fujifilm Cellular Dynamics Inc. 0,00 €
Iceta Instituto de Ciencias, Tecnologias e Agroambiente da Universidade do Porto 403 500 €
Inte:Ligand Software-Entwicklungs-UND Consulting GmbH 341 400 €
ITA-Suomen Yliopisto 804 900 €
Medizinische Universitaet Wien 372 200 €
Merck Sharp & Dohme Corp 0,00 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
UCB Biopharma 0,00 €
Universita Degli Studi Di Firenze 391 500 €
Universitat Wien 594 450 €
Universite Clermont Auvergne 429 400 €
Uppsala Universitet 307 400 €

https://cordis.europa.eu/project/id/821528

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.